Literature DB >> 30578403

Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant Klebsiella pneumoniae Bacteremia and Abscess in a Liver Transplant Recipient.

Vasilios Athans1, Elizabeth A Neuner2, Habiba Hassouna3, Sandra S Richter4, George Keller4, Mariana Castanheira5, Kyle D Brizendine3, Amy J Mathers6,7.   

Abstract

We report a case of a 24-year-old liver transplant recipient who developed hepatic artery thrombosis and graft failure, which was complicated by subphrenic abscess and persistent Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae bacteremia. Ceftazidime-avibactam treatment led to emergence of resistance, and alternative combination therapy failed due to persistent infection and toxicity. The infection resolved after initiation of meropenem-vaborbactam, which created a bridge to retransplantation. Treatment-emergent ceftazidime-avibactam resistance is increasingly recognized, suggesting a role for meropenem-vaborbactam.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Klebsiella pneumoniae carbapenemase; carbapenem-resistant Enterobacteriaceaezzm321990; carbapenemase-producing Klebsiella pneumoniaezzm321990; ceftazidime-avibactam; meropenem-vaborbactam

Mesh:

Substances:

Year:  2018        PMID: 30578403      PMCID: PMC6325210          DOI: 10.1128/AAC.01551-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.

Authors:  Mario Tumbarello; Enrico Maria Trecarichi; Francesco Giuseppe De Rosa; Maddalena Giannella; Daniele Roberto Giacobbe; Matteo Bassetti; Angela Raffaella Losito; Michele Bartoletti; Valerio Del Bono; Silvia Corcione; Giuseppe Maiuro; Sara Tedeschi; Luigi Celani; Chiara Simona Cardellino; Teresa Spanu; Anna Marchese; Simone Ambretti; Roberto Cauda; Claudio Viscoli; Pierluigi Viale
Journal:  J Antimicrob Chemother       Date:  2015-04-21       Impact factor: 5.790

Review 2.  Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes.

Authors:  David van Duin; Keith S Kaye; Elizabeth A Neuner; Robert A Bonomo
Journal:  Diagn Microbiol Infect Dis       Date:  2013-01-03       Impact factor: 2.803

3.  Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Ryan K Shields; M Hong Nguyen; Liang Chen; Ellen G Press; Barry N Kreiswirth; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

4.  Impaired Inhibition by Avibactam and Resistance to the Ceftazidime-Avibactam Combination Due to the D179Y Substitution in the KPC-2 β-Lactamase.

Authors:  Fabrice Compain; Michel Arthur
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

5.  Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in blaKPC-2-Harboring Klebsiella pneumoniae Sequence Type 307 Isolates.

Authors:  Marla J Giddins; Nenad Macesic; Medini K Annavajhala; Stephania Stump; Sabrina Khan; Thomas H McConville; Monica Mehta; Angela Gomez-Simmonds; Anne-Catrin Uhlemann
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

6.  Exploring colistin pharmacodynamics against Klebsiella pneumoniae: a need to revise current susceptibility breakpoints.

Authors:  Marilena Tsala; Sophia Vourli; Panagiota-Christina Georgiou; Spyros Pournaras; Athanasios Tsakris; George L Daikos; Johan W Mouton; Joseph Meletiadis
Journal:  J Antimicrob Chemother       Date:  2018-04-01       Impact factor: 5.790

7.  Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258.

Authors:  Brandon Kitchel; J Kamile Rasheed; Jean B Patel; Arjun Srinivasan; Shiri Navon-Venezia; Yehuda Carmeli; Alma Brolund; Christian G Giske
Journal:  Antimicrob Agents Chemother       Date:  2009-06-08       Impact factor: 5.191

8.  Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.

Authors:  Mical Paul; George L Daikos; Emanuele Durante-Mangoni; Dafna Yahav; Yehuda Carmeli; Yael Dishon Benattar; Anna Skiada; Roberto Andini; Noa Eliakim-Raz; Amir Nutman; Oren Zusman; Anastasia Antoniadou; Pia Clara Pafundi; Amos Adler; Yaakov Dickstein; Ioannis Pavleas; Rosa Zampino; Vered Daitch; Roni Bitterman; Hiba Zayyad; Fidi Koppel; Inbar Levi; Tanya Babich; Lena E Friberg; Johan W Mouton; Ursula Theuretzbacher; Leonard Leibovici
Journal:  Lancet Infect Dis       Date:  2018-02-16       Impact factor: 25.071

9.  Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering.

Authors:  Melissa D Barnes; Marisa L Winkler; Magdalena A Taracila; Malcolm G Page; Eric Desarbre; Barry N Kreiswirth; Ryan K Shields; Minh-Hong Nguyen; Cornelius Clancy; Brad Spellberg; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  MBio       Date:  2017-10-31       Impact factor: 7.867

10.  Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.

Authors:  Florian M Wagenlehner; Jack D Sobel; Paul Newell; Jon Armstrong; Xiangning Huang; Gregory G Stone; Katrina Yates; Leanne B Gasink
Journal:  Clin Infect Dis       Date:  2016-06-16       Impact factor: 9.079

View more
  24 in total

1.  Resistance to Ceftazidime/Avibactam plus Meropenem/Vaborbactam When Both Are Used Together Is Achieved in Four Steps in Metallo-β-Lactamase-Negative Klebsiella pneumoniae.

Authors:  Punyawee Dulyayangkul; Edward J A Douglas; Filip Lastovka; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

Review 2.  Is it time to move away from polymyxins?: evidence and alternatives.

Authors:  Rajeev Soman; Yamuna Devi Bakthavatchalam; Abinaya Nadarajan; Hariharan Triplicane Dwarakanathan; Ramasubramanian Venkatasubramanian; Balaji Veeraraghavan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-02       Impact factor: 3.267

Review 3.  Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".

Authors:  Krisztina M Papp-Wallace; Andrew R Mack; Magdalena A Taracila; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

4.  Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections.

Authors:  Ryan K Shields; Erin K McCreary; Rachel V Marini; Ellen G Kline; Chelsea E Jones; Binghua Hao; Liang Chen; Barry N Kreiswirth; Yohei Doi; Cornelius J Clancy; M Hong Nguyen
Journal:  Clin Infect Dis       Date:  2020-07-27       Impact factor: 9.079

Review 5.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

6.  Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections.

Authors:  Helen L Zhang; Leigh Cressman; Ebbing Lautenbach
Journal:  J Glob Antimicrob Resist       Date:  2021-11-12       Impact factor: 4.035

7.  Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Renee Ackley; Danya Roshdy; Jacqueline Meredith; Sarah Minor; William E Anderson; Gerald A Capraro; Christopher Polk
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

Review 8.  New Perspectives on Antimicrobial Agents: Cefiderocol.

Authors:  Erin K McCreary; Emily L Heil; Pranita D Tamma
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

9.  KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity.

Authors:  Laurent Poirel; Xavier Vuillemin; Mario Juhas; Amandine Masseron; Ursina Bechtel-Grosch; Simon Tiziani; Stefano Mancini; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

10.  KPC-Mediated Resistance to Ceftazidime-Avibactam and Collateral Effects in Klebsiella pneumoniae.

Authors:  Jacqueline Findlay; Laurent Poirel; Mario Juhas; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.